<DOC>
	<DOC>NCT02377895</DOC>
	<brief_summary>Single-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy and safety study using the Allergen BioCube (ABC).</brief_summary>
	<brief_title>Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Key Must be 18 years of age and provide written informed consent and sign the HIPAA form Must have history of allergic rhinitis Must have positive response to Allergen BioCube Key Must not have a significant illness such as moderate to severe allergic asthmatic reactions Must not have compromised lung function Must not use any disallowed medications Must not have been in an investigational study in the last 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>